BCRX 240920 8.00C (BCRX240920C8000) Stock Options, News & Quotes

US OptionsDetailed Quotes

BCRX240920C8000

Watchlist

0.12
+0.02+20.00%

15min DelayClose Sep 13 16:00 ET

0.22High0.10Low

Intraday

5D
Daily

News

BlackRock Inc. Expands Stake in BioCryst Pharmaceuticals
Yahoo FinanceSep 12 01:25 ET
Island Pharmaceuticals Signs Letteer of Intent to Acquire BioCryst's Antiviral Program
MT NewswiresSep 11 00:02 ET
BioCryst Presents Results on HAE Treatment and Patient Care at Global Symposium
BenzingaSep 6 03:02 ET
BioCryst Presents New ORLADEYO (Berotralstat) Data at 7th Bradykinin Symposium
GlobeNewswireSep 6 02:00 ET
'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio
Analysts NotebookSep 5 07:06 ET
Express News | BioCryst Appoints DR. Donald Fong Chief Medical Officer
ReutersSep 5 07:00 ET

Comments

Analysts Notebook

Sep 5 06:06

Columns 'Trump Trade' vs. 'Harris Trade': How They Could Shape Your Portfolio

The 2024 U.S. presidential race between former President Donald Trump and current Vice President Kamala Harris is still "incredibly close," according to the latest New York Times survey. As investors await the outcome of the November election, equity analysts are busy parsing through the candidates' pronouncements for clues on which stocks could benefit from their policies.
Jefferies analysts cited 10 possible policies that Tr...

Trump & Harris debate has just concluded! How could it affect the market?

Trytosaveabit

Jul 9 06:04

Update

$BioCryst Pharmaceuticals (BCRX.US)$ Reuters · 1 min ago BioCryst Pharmaceuticals- Orladeyo® (Berotralstat) Approved in Peru

Trytosaveabit

May 29 16:07

Insider buy

$BioCryst Pharmaceuticals (BCRX.US)$ Director ASELAGE STEVE purchased 2,500 shares of common stock on May 24, 2024 at an average price of $6.4 for a total value of $16,000.

Trytosaveabit

May 15 09:25

$BioCryst Pharmaceuticals (BCRX.US)$

Trytosaveabit

May 9 06:43

Update

$BioCryst Pharmaceuticals (BCRX.US)$ Benzinga· 1 min BioCryst Presents New Real-world Evidence Showing Significant Reductions In Healthcare Resource Utilization Among Patients With Hereditary Angioedema Following Initiation Of Orladeyo (Berotralstat